| Bioactivity | LH1753 is an orally active L-cystine crystallization inhibitor with an EC50 of 29.5 nM. LH1753 can be used for Cystinuria research[1]. |
| In Vivo | LH1753 (150 μmol/kg, 灌胃, 每日一次共八周) 可抑制 L-胱氨酸结石的形成，但对 Slc3a1 基因敲除的胱氨酸尿症小鼠模型的生长无影响[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 2650492-10-5 |
| Formula | C22H44Cl4N6O2S2 |
| Molar Mass | 630.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Longqin Hu, et al. 8-l-Cystinyl Bis(1,8-diazaspiro[4.5]decane) as an Orally Bioavailable l-Cystine Crystallization Inhibitor for Cystinuria, ACS Medicinal Chemistry Letters, Article ASAP |
LH1753
CAS: 2650492-10-5 F: C22H44Cl4N6O2S2 W: 630.57
LH1753 is an orally active L-cystine crystallization inhibitor with an EC50 of 29.5 nM. LH1753 can be used for Cystinuri
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.